MAP2K7 and non-small cell lung carcinoma: Based on these findings, we seek to evaluate the translational potential of new combinations for MET-aberrant NSCLC patients by predicting the population-level clinical response to emerging combinations involving MET inhibitors (e.g., capmatinib, crizotinib) and other kinase inhibitors (targeting PI3K, AKT, MEK, and ERK) (Figure 7G).